Thursday, 29 October 2026
Canberra closes allergy referrals, Mutation-tailored gene therapy pathway, Retatrutide tops semaglutide in trial
- 01
Canberra closes about 1000 paediatric allergy referrals
Canberra Health Services has closed approximately 1000 paediatric allergy referrals after updating its referral criteria and triage process, directing affected families to discuss care plans with a GP or paediatrician. The service said referrals were closed where children could be safely managed through alternative pathways, while some patients face waits of more than six years at its Allergy Clinic. The RACGP criticised the transfer of responsibility without adequate consultation or assurance that appropriate services were available. ACT Health Minister Dr Marisa Paterson said families concerned about a closed referral could contact the service for review, and children referred back would retain their place in the queue.
via RACGP newsGP · also covered by The Medical Republic
- 02
FDA proposes streamlined approvals for mutation-tailored gene therapies
The FDA has proposed a pathway allowing gene therapies targeting different mutations in the same disease-causing gene to build on an initial approval. A drugmaker could seek approval for a therapy targeting one mutation through a more traditional approach, then pursue clearance for therapies targeting other mutations using laboratory data rather than new clinical studies. The original application would define the parameters for later approvals in an “individualised feature space”. The draft guidance aims to support treatments for mutations so rare that traditional clinical trials may be impractical or impossible, as part of the FDA’s broader Rare Disease Framework Initiative.
via BioPharma Dive
- 03
Retatrutide outperformed semaglutide in phase 3 diabetes trial
Retatrutide outperformed semaglutide on glycaemic control and weight loss in a head-to-head phase 3 diabetes trial, Eli Lilly reported. After 80 weeks, weekly 12 mg retatrutide reduced blood sugar by an average 2.2 percentage points, significantly more than the 1.8-point reduction with semaglutide, while the difference for the 9 mg dose was statistically nominal. Average weight loss was 21% with 12 mg retatrutide and 20% with 9 mg, compared with 9% among semaglutide recipients. Adverse-effect-related discontinuations occurred in 8% of the 12 mg retatrutide group and 5% of the 9 mg group, versus 3% with semaglutide. Retatrutide acts on GLP-1, GIP and glucagon pathways and has not yet been approved.
via BioPharma Dive
- 04
Receptionist sentenced over $29,512 in fraudulent Medicare claims
A Tasmanian medical receptionist received 12 months’ home detention after pleading guilty to 108 counts of computer-related fraud involving $29,512.65 in false Medicare claims. Erin Grant entered false appointments into practice software from August 2021, lodged claims under eight doctors’ names and directed rebates to her personal debit card before cancelling the appointments. A clinic doctor uncovered the fraud in April 2022 after noticing an irregularity in his patient consultation record. Grant was ordered to repay the money, with Justice Stephen Estcourt describing the offending as serious because it breached the trust between employer and employee. Primary care accountant David Dahm argued that practices could strengthen internal controls by separating the creation and authorisation of invoices.
- 05
Bulk billing rebounds as longer GP consults remain underfunded
The proportion of GPs who bulk billed all patients more than doubled from 12% in 2025 to 26% in 2026, according to an RACGP survey of 2766 practising GPs. Almost two-thirds of Australians were bulk billed for all general practice care, up from 56% in 2024 and 2025 but below the 70% recorded in 2019. Average consultation time rose from 17.7 minutes in 2022 to 19.8 minutes in 2026, with GPs most commonly attributing longer appointments to patient presentation and care complexity. The RACGP said Medicare continued to disadvantage longer consultations, calculating rebates of $3.00 per minute for a 15-minute consultation and $2.33 per minute for a 55-minute consultation. Overall, 51% of GPs said finding enough time with patients was challenging, while 78% said the role was more professionally demanding than a decade earlier.
- 06
Healthcare satisfaction rises, but costs continue to delay care
Australians rated their overall healthcare satisfaction at 7.4 out of 10, the highest level since 2021 and the second consecutive increase. The Australian Healthcare Index surveyed 6,244 adults in June 2026 and found 67% had been bulk billed at their most recent GP visit, with bulk-billing availability the most cited reason for high satisfaction. Emergency department waiting times remained the leading concern, followed by out-of-pocket specialist costs, private health insurance value, workforce shortages and out-of-pocket GP costs. For the third consecutive survey, more than 70% said cost-of-living increases were shaping their healthcare decisions. Among those affected by financial pressure, 50% had missed or delayed dental care, 43% a specialist visit and 39% a GP appointment, while younger adults were particularly likely to attend GPs less often.
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.